160 related articles for article (PubMed ID: 7681857)
1. Expression of the human progenitor cell antigen CD34 (HPCA-1) distinguishes dermatofibrosarcoma protuberans from fibrous histiocytoma in formalin-fixed, paraffin-embedded tissue.
Kutzner H
J Am Acad Dermatol; 1993 Apr; 28(4):613-7. PubMed ID: 7681857
[TBL] [Abstract][Full Text] [Related]
2. CD34 and factor XIIIa in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans.
Abenoza P; Lillemoe T
Am J Dermatopathol; 1993 Oct; 15(5):429-34. PubMed ID: 7694515
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of HMGA1 and HMGA2 in dermatofibroma and dermatofibrosarcoma protuberans: potential diagnostic applications, and comparison with histologic findings, CD34, and factor XIIIa immunoreactivity.
Li N; McNiff J; Hui P; Manfioletti G; Tallini G
Am J Dermatopathol; 2004 Aug; 26(4):267-72. PubMed ID: 15249855
[TBL] [Abstract][Full Text] [Related]
4. LN-2 (CD74). A marker to distinguish atypical fibroxanthoma from malignant fibrous histiocytoma.
Lazova R; Moynes R; May D; Scott G
Cancer; 1997 Jun; 79(11):2115-24. PubMed ID: 9179057
[TBL] [Abstract][Full Text] [Related]
5. CD34 and factor-XIIIa immunoreactivity in dermatofibrosarcoma protuberans and dermatofibroma.
Goldblum JR; Tuthill RJ
Am J Dermatopathol; 1997 Apr; 19(2):147-53. PubMed ID: 9129699
[TBL] [Abstract][Full Text] [Related]
6. The Role of CD34 and D2-40 in the Differentiation of Dermatofibroma and Dermatofibrosarcoma Protuberans.
Sadullahoğlu C; Dere Y; Atasever TR; Öztop MT; Karaaslan Ö
Turk Patoloji Derg; 2017; 1(1):223-227. PubMed ID: 28832078
[TBL] [Abstract][Full Text] [Related]
7. Dermatofibrosarcoma protuberans is a unique fibrohistiocytic tumour expressing CD34.
Aiba S; Tabata N; Ishii H; Ootani H; Tagami H
Br J Dermatol; 1992 Aug; 127(2):79-84. PubMed ID: 1382538
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical expression of matrix metalloproteinases 1, 2, 9, and 14 in dermatofibrosarcoma protuberans and common fibrous histiocytoma (dermatofibroma).
Weinrach DM; Wang KL; Wiley EL; Laskin WB
Arch Pathol Lab Med; 2004 Oct; 128(10):1136-41. PubMed ID: 15387709
[TBL] [Abstract][Full Text] [Related]
9. Dermatofibroma and dermatofibrosarcoma protuberans: an immunohistochemical study reveals distinctive antigenic profiles.
Hsi ED; Nickoloff BJ
J Dermatol Sci; 1996 Jan; 11(1):1-9. PubMed ID: 8867761
[TBL] [Abstract][Full Text] [Related]
10. [Fibrosarcomatous dermatofibrosarcoma protuberans: a clinicopathological analysis of 12 cases].
Zhang J; Wu N; Xia C; Wei X; Shi QL; Zhou XJ; Ma J
Zhonghua Bing Li Xue Za Zhi; 2013 Nov; 42(11):753-7. PubMed ID: 24447553
[TBL] [Abstract][Full Text] [Related]
11. Dermatofibroma and dermatofibrosarcoma protuberans: differential expression of CD34 and factor XIIIa.
Cohen PR; Rapin RP; Farhood AI
Am J Dermatopathol; 1994 Oct; 16(5):573-4. PubMed ID: 7528477
[No Abstract] [Full Text] [Related]
12. Immunohistochemical characterization of dermatofibrosarcoma protuberans with practical applications for diagnosis and treatment.
Haycox CL; Odland PB; Olbricht SM; Piepkorn M
J Am Acad Dermatol; 1997 Sep; 37(3 Pt 1):438-44. PubMed ID: 9308560
[TBL] [Abstract][Full Text] [Related]
13. CD34 positivity in fibrosarcomas which arise in dermatofibrosarcoma protuberans.
Goldblum JR
Arch Pathol Lab Med; 1995 Mar; 119(3):238-41. PubMed ID: 7534057
[TBL] [Abstract][Full Text] [Related]
14. D2-40, a novel immunohistochemical marker in differentiating dermatofibroma from dermatofibrosarcoma protuberans.
Bandarchi B; Ma L; Marginean C; Hafezi S; Zubovits J; Rasty G
Mod Pathol; 2010 Mar; 23(3):434-8. PubMed ID: 20062007
[TBL] [Abstract][Full Text] [Related]
15. Tenascin differentiates dermatofibroma from dermatofibrosarcoma protuberans: comparison with CD34 and factor XIIIa.
Kahn HJ; Fekete E; From L
Hum Pathol; 2001 Jan; 32(1):50-6. PubMed ID: 11172295
[TBL] [Abstract][Full Text] [Related]
16. Dermatofibrosarcoma protuberans treated with Mohs surgery. A case with CD34 immunostaining variability.
Garcia C; Viehman G; Hitchcock M; Clark RE
Dermatol Surg; 1996 Feb; 22(2):177-9. PubMed ID: 8608381
[TBL] [Abstract][Full Text] [Related]
17. Assessment of diagnostic utility of anti-CD34 in soft tissue tumors.
Park HR; Park YK
J Korean Med Sci; 1995 Dec; 10(6):436-41. PubMed ID: 8924229
[TBL] [Abstract][Full Text] [Related]
18. CD34 immunoreactivity distinguishes between scar tissue and residual tumor in re-excisional specimens of dermatofibrosarcoma protuberans.
Prieto VG; Reed JA; Shea CR
J Cutan Pathol; 1994 Aug; 21(4):324-9. PubMed ID: 7528229
[TBL] [Abstract][Full Text] [Related]
19. Stromelysin-3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans: comparison with factor XIIIa and CD34.
Kim HJ; Lee JY; Kim SH; Seo YJ; Lee JH; Park JK; Kim MH; Cinn YW; Cho KH; Yoon TY
Br J Dermatol; 2007 Aug; 157(2):319-24. PubMed ID: 17596171
[TBL] [Abstract][Full Text] [Related]
20. Expression of MMP-2, MMP-9 and MMP-11 in dermatofibroma and dermatofibrosarcoma protuberans.
Chen YT; Chen WT; Huang WT; Wu CC; Chai CY
Kaohsiung J Med Sci; 2012 Oct; 28(10):545-9. PubMed ID: 23089320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
